Ademi LLP Probes Crinetics Pharmaceuticals Valuation in Vertex Deal

Under the terms of the announced transaction, Crinetics shareholders are set to receive $85.00 per share in cash, valuing the company at approximately $8.8 billion net of acquired cash. Ademi LLP’s investigation focuses on potential breaches of fiduciary duty by the board of directors, specifically questioning whether the current agreement imposes restrictive penalties on potential competing bids.

Legal experts are examining whether the board prioritized these change-of-control provisions at the expense of minority shareholders. The firm is currently soliciting information from investors regarding the conduct of the board throughout the negotiation process.